Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients

Sang Oh Lee, Robert A. Brown, Raymund R Razonable

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background. The clinical relevance of chromosomally integrated human herpesvirus-6 (CIHHV-6) after transplantation is not known. This study was aimed to determine the potential role of CIHHV-6 on the occurrence of other infections, allograft rejection, and outcomes after liver transplantation. Methods. A real-time quantitative human herpesvirus-6 (HHV-6) polymerase chain reaction assay was performed on whole blood samples of 548 liver transplant recipients. Clinical characteristics and outcomes of the patients with CIHHV-6 (defined as HHV-6 levels >1×10 genomes/mL) were compared with those of patients with low-level or no HHV-6 DNAemia. Results. Seven had CIHHV-6, 35 had low-level HHV-6 DNAemia, and 506 had no HHV-6 DNAemia before liver transplantation. Bacterial infection was significantly more common in the CIHHV-6 group compared with the group without HHV-6 (71.4% vs. 31.4%; P=0.04). A higher rate of allograft rejection was observed in the CIHHV-6 group compared with the group with low-level HHV-6 DNAemia (71.4% vs. 37.1%; P=0.12) and those without HHV-6 DNAemia (71.4% vs. 42.9%; P=0.25), although these differences did not reach statistical significance. Other opportunistic infections and outcomes were not significantly different between the CIHHV-6 group and the non-CIHHV-6 groups. Conclusion. Patients with CIHHV-6 may be at increased risk of indirect HHV6 effects after transplantation. This clinically relevant observation warrants confirmation using a larger cohort of transplant recipients.

Original languageEnglish (US)
Pages (from-to)224-229
Number of pages6
JournalTransplantation
Volume92
Issue number2
DOIs
StatePublished - Jul 27 2011

Fingerprint

Human Herpesvirus 6
Liver
Transplant Recipients
Liver Transplantation
Allografts
Transplantation

Keywords

  • Chromosomal integration
  • Human herpesvirus-6
  • Infection
  • Liver transplantation
  • Mortality
  • Rejection

ASJC Scopus subject areas

  • Transplantation

Cite this

Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. / Lee, Sang Oh; Brown, Robert A.; Razonable, Raymund R.

In: Transplantation, Vol. 92, No. 2, 27.07.2011, p. 224-229.

Research output: Contribution to journalArticle

@article{a0ffc8d7d00343db9d60cfd951740924,
title = "Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients",
abstract = "Background. The clinical relevance of chromosomally integrated human herpesvirus-6 (CIHHV-6) after transplantation is not known. This study was aimed to determine the potential role of CIHHV-6 on the occurrence of other infections, allograft rejection, and outcomes after liver transplantation. Methods. A real-time quantitative human herpesvirus-6 (HHV-6) polymerase chain reaction assay was performed on whole blood samples of 548 liver transplant recipients. Clinical characteristics and outcomes of the patients with CIHHV-6 (defined as HHV-6 levels >1×10 genomes/mL) were compared with those of patients with low-level or no HHV-6 DNAemia. Results. Seven had CIHHV-6, 35 had low-level HHV-6 DNAemia, and 506 had no HHV-6 DNAemia before liver transplantation. Bacterial infection was significantly more common in the CIHHV-6 group compared with the group without HHV-6 (71.4{\%} vs. 31.4{\%}; P=0.04). A higher rate of allograft rejection was observed in the CIHHV-6 group compared with the group with low-level HHV-6 DNAemia (71.4{\%} vs. 37.1{\%}; P=0.12) and those without HHV-6 DNAemia (71.4{\%} vs. 42.9{\%}; P=0.25), although these differences did not reach statistical significance. Other opportunistic infections and outcomes were not significantly different between the CIHHV-6 group and the non-CIHHV-6 groups. Conclusion. Patients with CIHHV-6 may be at increased risk of indirect HHV6 effects after transplantation. This clinically relevant observation warrants confirmation using a larger cohort of transplant recipients.",
keywords = "Chromosomal integration, Human herpesvirus-6, Infection, Liver transplantation, Mortality, Rejection",
author = "Lee, {Sang Oh} and Brown, {Robert A.} and Razonable, {Raymund R}",
year = "2011",
month = "7",
day = "27",
doi = "10.1097/TP.0b013e318222444a",
language = "English (US)",
volume = "92",
pages = "224--229",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients

AU - Lee, Sang Oh

AU - Brown, Robert A.

AU - Razonable, Raymund R

PY - 2011/7/27

Y1 - 2011/7/27

N2 - Background. The clinical relevance of chromosomally integrated human herpesvirus-6 (CIHHV-6) after transplantation is not known. This study was aimed to determine the potential role of CIHHV-6 on the occurrence of other infections, allograft rejection, and outcomes after liver transplantation. Methods. A real-time quantitative human herpesvirus-6 (HHV-6) polymerase chain reaction assay was performed on whole blood samples of 548 liver transplant recipients. Clinical characteristics and outcomes of the patients with CIHHV-6 (defined as HHV-6 levels >1×10 genomes/mL) were compared with those of patients with low-level or no HHV-6 DNAemia. Results. Seven had CIHHV-6, 35 had low-level HHV-6 DNAemia, and 506 had no HHV-6 DNAemia before liver transplantation. Bacterial infection was significantly more common in the CIHHV-6 group compared with the group without HHV-6 (71.4% vs. 31.4%; P=0.04). A higher rate of allograft rejection was observed in the CIHHV-6 group compared with the group with low-level HHV-6 DNAemia (71.4% vs. 37.1%; P=0.12) and those without HHV-6 DNAemia (71.4% vs. 42.9%; P=0.25), although these differences did not reach statistical significance. Other opportunistic infections and outcomes were not significantly different between the CIHHV-6 group and the non-CIHHV-6 groups. Conclusion. Patients with CIHHV-6 may be at increased risk of indirect HHV6 effects after transplantation. This clinically relevant observation warrants confirmation using a larger cohort of transplant recipients.

AB - Background. The clinical relevance of chromosomally integrated human herpesvirus-6 (CIHHV-6) after transplantation is not known. This study was aimed to determine the potential role of CIHHV-6 on the occurrence of other infections, allograft rejection, and outcomes after liver transplantation. Methods. A real-time quantitative human herpesvirus-6 (HHV-6) polymerase chain reaction assay was performed on whole blood samples of 548 liver transplant recipients. Clinical characteristics and outcomes of the patients with CIHHV-6 (defined as HHV-6 levels >1×10 genomes/mL) were compared with those of patients with low-level or no HHV-6 DNAemia. Results. Seven had CIHHV-6, 35 had low-level HHV-6 DNAemia, and 506 had no HHV-6 DNAemia before liver transplantation. Bacterial infection was significantly more common in the CIHHV-6 group compared with the group without HHV-6 (71.4% vs. 31.4%; P=0.04). A higher rate of allograft rejection was observed in the CIHHV-6 group compared with the group with low-level HHV-6 DNAemia (71.4% vs. 37.1%; P=0.12) and those without HHV-6 DNAemia (71.4% vs. 42.9%; P=0.25), although these differences did not reach statistical significance. Other opportunistic infections and outcomes were not significantly different between the CIHHV-6 group and the non-CIHHV-6 groups. Conclusion. Patients with CIHHV-6 may be at increased risk of indirect HHV6 effects after transplantation. This clinically relevant observation warrants confirmation using a larger cohort of transplant recipients.

KW - Chromosomal integration

KW - Human herpesvirus-6

KW - Infection

KW - Liver transplantation

KW - Mortality

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=79960336689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960336689&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318222444a

DO - 10.1097/TP.0b013e318222444a

M3 - Article

C2 - 21629177

AN - SCOPUS:79960336689

VL - 92

SP - 224

EP - 229

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -